NCT04575922 - Nivolumab+Ipilimumab+RT in MSS mCRC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions

Metastatic Microsatellite Stable Colorectal Cancer

Interventions

DRUG

Nivolumab

Administered into vein by intravenous infusion every 2 weeks over 6 week study cycle.

DRUG

Ipilimumab

Administered into vein by intravenous infusion day 1 of each 6 week study cycle.

RADIATION

Radiation Therapy

3 radiation treatments, every other weekday or 2 days during week 1 of cycle 1 only of study.

Trial Locations (3)

Massachusetts General Hospital Cancer Center, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston